Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors for GEM + nab-PTX combination therapy in elderly patients with pancreatic cancer.
Authors
Kazuki Watabe
Chiba University Hospital, Chiba, Chiba, Japan
Kazuki Watabe , Izumi Ohno , Miho Sakai , Tomoya Takahashi , Nana Yamada , Shodai Tohyama , Yu Sekine , Jihei Sugihara , Mayu Ohuchi , Hiroki Nagashima , Koji Takahashi , Kohichiro Okitsu , Motoyasu Kan , Hiroshi Ohyama , Masayuki Ohtsuka , Naoya Kato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 678)
DOI
10.1200/JCO.2024.42.3_suppl.678
Abstract #
678
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2017 Gastrointestinal Cancers Symposium
Clinical outcome of modified FOLFIRINOX versus Gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
First Author: Kazuo Watanabe
Poster
2016 ASCO Annual Meeting
Comparative effectiveness of FOLFIRINOX or nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: A population-based analysis.
First Author: Ying Wang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.
First Author: Yan-Shen Shan